Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rollover safety study of luspatercept in adults previously enrolled in luspatercept trials
jRCT2031220422Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of luspatercept in anemia of myelodysplastic syndromes and myelophthisis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse events, Progression to high-risk disease or acute myeloid leukemia and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
luspatercept
03
Conditions
anemia of myelodysplastic syndromesmyelophthisis
Beyond the preview
Go deeper on jRCT2031220422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220422.